E
E.F. Smit
Researcher at University of Groningen
Publications - 103
Citations - 2544
E.F. Smit is an academic researcher from University of Groningen. The author has contributed to research in topics: Lung cancer & Internal medicine. The author has an hindex of 24, co-authored 86 publications receiving 2310 citations.
Papers
More filters
Journal ArticleDOI
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".
David Planchard,Sanjay Popat,Keith M. Kerr,Silvia Novello,E.F. Smit,Corinne Faivre-Finn,Tony Mok,Martin Reck,P. Van Schil,Matthew D. Hellmann,Solange Peters +10 more
TL;DR: Department of Medical Oncology, Thoracic Group, Gustave-Roussy Villejuif, France; Royal Marsden Hospital, London; Aberdeen Royal Infirmary, Aberdeen University Medical School, Aberdeen, UK; Department of Oncologists, University of Turin, San Luigi Hospital, Orbassano, Italy.
Journal ArticleDOI
Treatment of Brain Metastases of Small-Cell Lung Cancer: Comparing Teniposide and Teniposide With Whole-Brain Radiotherapy—A Phase III Study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group
Pieter E. Postmus,Hanny Haaxma-Reiche,E.F. Smit,Hendricus Groen,H Karnicka,T Lewinski,J. Van Meerbeeck,M. Clerico,Anna Gregor,Desmond Curran,Tarek Sahmoud,Anne Kirkpatrick,G. Giaccone +12 more
TL;DR: Adding WBRT to teniposide results in a much higher response rate of brain metastases and in a longer time to progression of brain cancer metastases than tenipOSide alone.
Journal ArticleDOI
A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer
TL;DR: Paclitaxel is active in drug-resistant SCLC; further investigation in combination with other active agents in this poor prognosis group is appropriate.
Journal ArticleDOI
Multidrug resistance related molecules in human and murine lung.
George L. Scheffer,Aclm Pijnenborg,E.F. Smit,Michael Müller,Dirkje S. Postma,Wim Timens,P. van der Valk,de Elisabeth G. E. Vries,R.J. Scheper +8 more
TL;DR: Results show that the "classic" MDR related molecules, MDR1 P-gp, MRP1, and MVP, should be considered the most important transporters in normal lung physiology.
Journal ArticleDOI
Gemcitabine and Cisplatin as Induction Regimen for Patients With Biopsy-Proven Stage IIIA N2 Non–Small-Cell Lung Cancer: A Phase II Study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955)
N. van Zandwijk,E.F. Smit,Gijsbert W.P.M. Kramer,Franz M.N.H. Schramel,Steven Gans,J. Festen,A. Termeer,N.J. J. Schlosser,C. Debruyne,Desmond Curran,G. Giaccone +10 more
TL;DR: In patients with N2 stage IIIA NSCLC, GC is a highly active and well-tolerated induction regimen and should be explored in combination with surgery or radiotherapy in stage I and II patients.